Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) —Usefulness and limitations in “clinical reality”—
- 1 June 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Nuclear Medicine
- Vol. 17 (4), 261-279
- https://doi.org/10.1007/bf02988521
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Fluorodeoxyglucose Positron Emission Tomography and the Prognosis of Pancreatic CarcinomaScandinavian Journal of Gastroenterology, 2000
- Autoimmune PancreatitisJournal of Computer Assisted Tomography, 1998
- 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinomaCancer, 1997
- Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor modelsNuclear Medicine and Biology, 1996
- Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.Gut, 1995
- Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problemEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- PET with fluorine-18 deoxyglucose for pancreatic diseaseThe Lancet, 1992
- Familial Pancreatic CancerPancreas, 1992
- Over-expression of facilitative glucose transporter genes in human cancerBiochemical and Biophysical Research Communications, 1990